Limited-stage vs extensive-stage (small-cell lung cancer)
Small-cell lung cancer uses a two-way split instead of the usual four stages: limited (confined to one side of the chest and treatable within one radiation field, about a third of patients) or extensive (everything else).
Limited-stage disease receives concurrent platinum-etoposide and thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily) with curative intent, now followed by durvalumab consolidation (ADRIATIC), and cures 25-35%; extensive-stage disease receives platinum-etoposide with atezolizumab or durvalumab (IMpower133, CASPIAN), responds in most patients and relapses in most within a year, with tarlatamab now the preferred second-line drug. Prophylactic cranial irradiation or MRI surveillance follows response in both. TNM staging is applied in parallel but the two-stage system still drives treatment.
Pages like this
not linked directly; found by shared links- TrialPACIFIC
Shares Consolidation therapy, Chemoradiation (chemoradiotherapy, CRT), Durvalumab.
- TrialADRIATIC
Shares Prophylactic cranial irradiation vs MRI surveillance, Durvalumab, Small-cell lung cancer.
- TrialDeLLphi-305
Shares Tarlatamab, Durvalumab, Small-cell lung cancer.
- IdeaMRI surveillance replaces prophylactic cranial irradiation in SCLC
Shares Prophylactic cranial irradiation vs MRI surveillance, Small-cell lung cancer.
- PairingChemo-immunotherapy induction → maintenance intensification (SCLC)
Shares Tarlatamab, Atezolizumab, Small-cell lung cancer.
- TermLimited-stage vs extensive-stage (SCLC)
Shares Prophylactic cranial irradiation vs MRI surveillance, Small-cell lung cancer.
- TermProphylactic cranial irradiation (PCI)
Shares Prophylactic cranial irradiation vs MRI surveillance, Small-cell lung cancer.
- TrialDeLLphi-304
Shares Tarlatamab, Small-cell lung cancer.